Cardiol Therapeutics

Cardiol Therapeutics, Inc. is a clinical-stage life sciences company focused on the research and clinical of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. Its lead product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. The firm is conducting clinical studies to evaluate the efficacy and safety of CardiolRx in diseases affecting the heart: a Phase II multi-national, randomized, double-blind, placebo-controlled trial (the ARCHER trial) in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis. It is also involved in developing a novel subcutaneously administered drug formulation of cannabidiol intended for use in heart failure. The company was founded by David Elsley, Eldon Smith, and Anthony Bolton on January 19, 2017 and is headquartered in Oakville, Canada.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

After losing some value lately, a hammer chart pattern has been formed for Cardiol Therapeutics Inc. (CRDL), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

Cardiol Therapeutics Inc. (CRDL) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?

Cardiol Therapeutics Inc. (CRDL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Cardiol Therapeutics Inc. (CRDL) Upgraded to Buy: Here's What You Should Know

Toronto, Ontario--(Newsfile Corp. - August 9, 2023) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, is pleased to announce that Cardiol's President and CEO, David Elsley, will present a company overview which will be broadcast live at the Canaccord Genuity 43rd Annual Growth Conference, at the InterContinental Boston Hotel, on August 10, 2023, at 11:00 a.m. EDT. Date: Thursday, August 10, 2023 Time: 11:00 a.m.

Cardiol Therapeutics to Present at Canaccord Genuity 43rd Annual Growth Conference

Oakville, Ontario--(Newsfile Corp. - June 29, 2023) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, announces the results from its Annual General Meeting of Shareholders (the "AGM") held virtually via live audio webcast, on June 28, 2023. Shareholders voted in favour of all management resolutions proposed in the Company's Information Circular.

Cardiol Therapeutics Reports Results of 2023 Annual General Meeting

Oakville, Ontario--(Newsfile Corp. - June 27, 2023) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, today is pleased to announce that the Company's virtual Annual General Meeting of Shareholders (the "AGM") will be webcast on June 28, 2023, at 4:30 p.m. EDT. Cardiol Therapeutics 2023 AGM When: June 28, 2023, at 4:30 p.m.

Cardiol Therapeutics to Webcast Virtual Annual General Meeting on June 28th at 4:30 p.m. EDT

Cardiol Therapeutics (TSX:CRDL, NASDAQ:CRDL) has retained a ‘Buy' rating with an increased price target from Canaccord Genuity (TSX:CF, LSE:CF) analysts following the release of its first-quarter results. As of March 31, 2023, Canaccord said Cardiol had cash and cash equivalents of C$49.5 million, which the company's management believes will be sufficient to achieve corporate milestones and fund operations into the second quarter of 2026.

Cardiol Therapeutics earns higher price target from broker as it ends 1Q with sufficient cash to advance CardioRx candidate

Cardiol Therapeutics (TSX:CRDL, NASDAQ:CRDL) Inc CEO David Elsley told investors in a year-end 2022 update on operations that the life sciences company has made “important progress” with the development of CardiolRx, its lead drug candidate for the treatment of inflammation and fibrosis in heart disease. The Oakville, Ontario-based company issued the update following the filing of its audited financial statements for the year ended December 31, 2022.

Cardiol Therapeutics offers an update on operations as it advances the development of its lead drug candidate CardiolRx

Initiated patient enrollment in a Phase II open-label clinical trial investigating the safety, tolerability, and efficacy of CardiolRx™ in patients with recurrent pericarditis - a debilitating heart disease associated with chest pain, shortness of breath and fatigue, resulting in markedly reduced quality of life, emergency department visits, and hospitalizations Initiated patient enrollment in the ARCHER Trial - a Phase II multi-national, randomized, placebo-controlled clinical trial evaluating the safety and efficacy of CardiolRx™ in patients with acute myocarditis, an important cause of acute and sudden heart failure in young adults and a leading cause of sudden cardiac death in people less than 35 years of age Data presented at the late-breaking scientific sessions of The American Heart Association 2022 demonstrating the cardioprotective effects of CardiolRx™ in a model of acute pericarditis Pre-clinical study results presented at The Annual Scientific Meeting of the Heart Failure Society of America demonstrating CardiolRx™ inhibits and promotes reversal mechanisms leading to cardiac fibrosis Made key appointments to the Board of Directors, adding extensive and diversified experience to provide additional independent guidance and stewardship to oversee the Company's continued growth and development Appointed thought leaders in cardiovascular medicine to its Scientific Advisory Board Cash and cash equivalents of $59.5 million as of December 31, 2022, providing capital to achieve corporate milestones and fund operations into 2026 Oakville, Ontario--(Newsfile Corp. - March 29, 2023) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, today announces its year-end 2022 update on operations following the filing of its audited Financial Statements and Management's Discussion and Analysis for the year ended December 31, 2022. Both are available under the Company's profile on SEDAR at sedar.com and on the Company's website at cardiolrx.com.

Cardiol Therapeutics Announces Year-End 2022 Update on Operations

Cardiol Therapeutics (TSX:CRDL, NASDAQ:CRDL) said that new study results have demonstrated the cardioprotective effects of pharmaceutically manufactured cannabidiol. Study results from one of Cardiol's international collaborating research centers demonstrated that cannabidiol – the active ingredient in Cardiol's lead drug CardiolRx – significantly prevents cardiac dysfunction and the development of fibrosis and cardiomyocyte hypertrophy in a pre-clinical model of heart failure and reduces expression of key inflammatory and fibrotic markers.

Cardiol Therapeutics says new study results highlight the cardioprotective effects of cannabidiol

Results Demonstrate Cannabidiol Improved Cardiac Function, Reduced its Inflammatory State, and Prevented the Development of Hypertrophy and Fibrosis in Heart Tissue Data Presented at The American College of Cardiology's 72 nd Annual Scientific Session Together with the World Congress of Cardiology Oakville, Ontario--(Newsfile Corp. - March 7, 2023) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases, announced study results from one of its international collaborating research centers demonstrating that its pharmaceutically manufactured cannabidiol significantly prevents cardiac dysfunction and the development of fibrosis and cardiomyocyte hypertrophy in a pre-clinical model of heart failure and reduces expression of key inflammatory and fibrotic markers. Cannabidiol is the active pharmaceutical ingredient in CardiolRx™, the Company's lead investigational oral drug candidate currently in Phase II clinical trials for recurrent pericarditis and acute myocarditis, and in its novel subcutaneously administered drug formulation intended for use in heart failure and currently in pre-clinical development.

Cardiol Therapeutics Announces Study Results from Collaborating Research Center Demonstrating Cardioprotective Effects of Cannabidiol in a Model of Heart Failure

Cardiol Therapeutics Inc (TSX:CRDL, NASDAQ:CRDL) said it has enrolled the first patient in its Phase II study evaluating CardiolRx for the treatment of recurrent pericarditis. The company-sponsored Phase II open-label pilot study is investigating the tolerance, safety, and efficacy of CardiolRx in patients with recurrent pericarditis – inflammation of the membrane that surrounds the heart, known as the pericardium.

Cardiol Therapeutics enrolls first patient in Phase II CardiolRx study on recurrent pericarditis

The Cleveland Clinic Recruits First Participant in the Multi-center U.S. StudyOakville, Ontario--(Newsfile Corp. - January 17, 2023) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases, announced today that the first patient has been enrolled in the Company-sponsored Phase II open-label pilot study (NCT05494788) investigating the tolerance, safety, and efficacy of CardiolRx™ in patients with recurrent pericarditis.

Cardiol Therapeutics Announces First Patient Enrolled in Phase II Study Evaluating CardiolRx(TM) for the Treatment of Recurrent Pericarditis

Cardiol Therapeutics (TSX:CRDL, NASDAQ:CRDL) Inc revealed that it had initiated a Phase II open-label pilot study to investigate the safety and effectiveness of its lead product candidate CardiolRx in patients with recurrent pericarditis, which refers to inflammation of the pericardium, the membrane or sac that surrounds the heart to hold it in place and help it to work. In addition to standard safety assessments, the Oakville, Ontario-based clinical-stage life sciences company said the study is designed to evaluate improvement in objective measures of disease, and during an extension period, assess the feasibility of a weaning concomitant background therapy including corticosteroids, while taking CardiolRx.

Cardiol Therapeutics kicks off a multi-center Phase II pilot study of CardiolRx for the treatment of recurrent pericarditis

The Cleveland Clinic and the Mayo Clinic Study Sites have been Initiated and are Eligible to Recruit ParticipantsInitiation of Additional U.S. Cardiovascular Research Centers is Planned for Q1, 2023 Oakville, Ontario--(Newsfile Corp. - December 12, 2022) - Cardiol Therapeutics Inc.

Cardiol Therapeutics Commences Multi-Center Phase II Pilot Study of CardiolRx(TM) for the Treatment of Recurrent Pericarditis

Cardiol Therapeutics Inc. (CRDL) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

Here's Why Cardiol Therapeutics Inc. (CRDL) Could be Great Choice for a Bottom Fisher

Cardiol Therapeutics (TSX:CRDL, NASDAQ:CRDL) Inc revealed new study results highlighting the protective effects of CardiolRx in a model of acute pericarditis. The study demonstrated that pharmaceutically manufactured cannabidiol – the active pharmaceutical ingredient in CardiolRx – significantly reduced pericardial effusion and thickening in a pre-clinical model of acute pericarditis, according to a statement.

Cardiol Therapeutics unveils new study data highlighting protective effects of CardiolRx in acute pericarditis

Cardiol Therapeutics Inc (TSX:CRDL, NASDAQ:CRDL) has said it will prioritize its Phase II clinical programs focused on developing CardiolRx for two underserved diseases affecting the heart - acute myocarditis and recurrent pericarditis - and announced that its cash runway now extends into 2026. The company also said it will discontinue its LANCER trial, which was designed to investigate the cardioprotective properties of CardiolRx in patients hospitalized with COVID-19 who have a prior history of, or risk factors for, cardiovascular disease, due to a continuous decline in the number of eligible patients, and a lower than anticipated event rate in the study.

Cardiol Therapeutics to prioritize its Phase II clinical programs focused on developing CardiolRx for two underserved diseases affecting the heart

Cardiol Therapeutics says to prioritize its Phase II clinical programs focused on developing CardiolRx for two underserved diseases affecting the heart

Discontinues LANCER Trial due to Lack of Eligible Patients for RecruitmentCash Runway Now Extends into 2026Oakville, Ontario--(Newsfile Corp. - October 25, 2022) -  Cardiol Therapeutics Inc.

Cardiol Therapeutics Prioritizes Phase II Clinical Programs in Underserved Heart Diseases

Cardiol Therapeutics (TSX:CRDL, NASDAQ:CRDL) Inc has revealed new study results that demonstrate the active pharmaceutical ingredient in CardiolRx inhibits, and promotes, the reversal of mechanisms known to play a role in the occurrence and development of fibrotic cardiovascular disease. Previous research showed that CardiolRx – the company's oral pharmaceutical that is being clinically developed for use in cardiovascular disease – preserves cardiac function in a pre-clinical model of heart failure.

Cardiol Therapeutics unveils new preclinical study results providing evidence of cardioprotective properties of CardiolRx

Data Presented at The Annual Scientific Meeting of the Heart Failure Society of America September 30th, 2022Oakville, Ontario--(Newsfile Corp. - October 3, 2022) - Cardiol Therapeutics Inc.

Cardiol Therapeutics Announces Pre-Clinical Study Results Demonstrating CardiolRx(TM) Inhibits and also Promotes Reversal of Mechanisms Leading to Cardiac Fibrosis

Oakville, Ontario--(Newsfile Corp. - September 28, 2022) - Cardiol Therapeutics Inc.

Cardiol Therapeutics Announces Poster Presentation at The Annual Scientific Meeting of the Heart Failure Society of America

Cardiol Therapeutics (TSX:CRDL, NASDAQ:CRDL) Inc. announced that the first patient has been enrolled in ARCHER, a Phase 2 trial designed to study the safety and tolerability of the oral cannabinoid formulation CardiolRx in patients with acute myocarditis.

Cardiol Therapeutics says first patient enrolled in acute myocarditis trial of its oral cannabinoid formulation CardiolRx

Multi-center, international, double-blind, randomized, placebo-controlled trial to enroll 100 patientsOakville, Ontario--(Newsfile Corp. - August 3, 2022) - Cardiol Therapeutics Inc.

Cardiol Therapeutics Announces First Patient Enrolled in ARCHER, a Phase II Clinical Trial of CardiolRx(TM) for Treatment of Acute Myocarditis

Oakville, Ontario--(Newsfile Corp. - June 29, 2022) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of cannabidiol as an anti-inflammatory and anti-fibrotic therapy for the treatment of cardiovascular diseases ("CVD"), announces the results from its Annual General Meeting of Shareholders (the "AGM") held virtually via live audio webcast, on June 28, 2022. Shareholders voted in favour of all management...

News for Cardiol Therapeutics Stock (CRDL)